NCT07459920 2026-03-10
CAPTURE
National Cancer Institute, Naples
Phase 2 Not yet recruiting
Clinical Trials
22 trialsNCT07293754 2026-02-17
RaPTR-101
Repertoire Immune Medicines
Phase 1/2 Recruiting
NCT07391644 2026-02-06
A Study of JSKN027 in Patients With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT06150183 2026-01-23
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
BioNTech SE
Phase 1 Active not recruiting
NCT07326488 2026-01-08
A Study of MHB009C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Not yet recruiting
NCT07192107 2025-09-25
A Study of MHB042C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT07077252 2025-07-22
Phase I/II Study of SCTB39G in Advanced Solid Tumours
Sinocelltech Ltd.
Phase 1/2 Not yet recruiting
NCT07050641 2025-07-04
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
Sinocelltech Ltd.
Phase 1/2 Recruiting
NCT07045454 2025-07-01
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1 Recruiting
NCT05477849 2025-04-01
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Virogin Biotech Ltd.
Phase 1 Recruiting
NCT06713148 2025-02-06
Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors
Fudan University
Phase EARLY_PHASE1 Not yet recruiting
NCT06718946 2025-02-06
Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors
Fudan University
Phase EARLY_PHASE1 Recruiting
NCT05098405 2025-01-30
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Molecular Partners AG
Phase 1 Terminated
NCT06592417 2024-09-19
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Recruiting
NCT04165590 2024-02-20
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
CAS Lamvac Biotech Co., Ltd.
Phase 1/2 Recruiting
NCT06166472 2023-12-12
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
Akeso
Phase 1 Not yet recruiting
NCT05396339 2023-07-19
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT05911984 2023-06-22
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Unknown
NCT03662815 2021-11-16
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT04864379 2021-04-28
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT04275050 2020-02-19
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03171220 2017-06-06
NRT-01
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown